ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1463	National Cancer Institute	Html	en	Renal Cell Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of renal cell cancer.	2-week washout period 0.566416 Transitional Cell Cancer 0.481465 treatment 0.601534 Patient Preference Study 0.474292 sunitinib treatment 0.529856 10-week treatment period 0.482517 VEGF receptors 0.467264 well-differentiated renal adenocarcinomas 0.509726 pazopanib arm 0.470964 sunitinib side effects 0.517044 true treatment break 0.474342 primary endpoint 0.499973 patients preferred pazopanib 0.531227 immediately surrounding tissue 0.462945 6-week treatment cycle 0.515867 trial 0.472067 Late tumor recurrence 0.47026 Pazopanib Versus Sunitinib 0.55357 cytoreductive nephrectomy extends 0.466923 High-dose IL-2 0.463042 patient treatment 0.463771 occasional selected patients 0.50375 overall survival 0.481487 rating scale 0.463587	toxic effects 0.499682 axitinib versus sorafenib 0.467683 sorafenib patients 0.470445 sunitinib 0.625595 renal cell cancer 0.570239 recurrent renal cell 0.504482 metastatic disease 0.476849 external-beam radiation therapy 0.463579 patients 0.74513 Metastatic Kidney Cancer 0.465785 initial cytoreductive nephrectomy 0.466065 median PFS time 0.4636 renal adenomas 0.481736 4-week treatment cycle 0.477666 renal cell carcinoma 0.969838 renal cell carcinoma. 0.553709 transitional cell carcinomas 0.485832 clear-cell renal cell 0.607225 renal cell cancers 0.532142 renal pelvis 0.520062 10-week treatment periods 0.476333 metastatic renal cell 0.598995 renal cell carcinomas 0.527788	CLICK HERE
1524	National Cancer Institute	Html	en	Endometrial Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of endometrial cancer.	cancer treatment 0.541916 Lymph node dissection 0.478324 metastatic endometrial cancer 0.510561 body 0.511838 PDQ cancer information 0.531329 clinical trial search 0.465384 uterus 0.585793 endometrial cancer spreads 0.509404 mTOR inhibitors 0.464666 clinical trials 0.736061 cancer information summary 0.508345 clinical trial 0.5843 Low-risk endometrial cancer 0.501844 breast cancer patients 0.483969 patients 0.494506 NCI PDQ cancer 0.479485 malignant tumor cells 0.467809 lymph nodes 0.52827 endometrial hyperplasia 0.468477 radiation therapy 0.605187 Treatment Editorial Board 0.469208 endometrial cancer 0.889926 radical hysterectomy 0.471844 treatment 0.622425 cancer prevention 0.463817	new cancer treatments 0.470535 NCI-supported cancer 0.463476 cancer cells 0.753566 Cancer Information Service 0.471559 specific cancer cells 0.479989 treatment clinical trials 0.48357 High-risk endometrial cancer 0.500552 endometrial tissue 0.464689 National Cancer Institute 0.508844 new treatment 0.504217 cervix 0.474629 external radiation therapy 0.482834 non-polyposis colon cancer 0.477796 tissue samples 0.463584 cancer research process 0.465542 cancer clinical trials 0.501833 stage 0.522219 Endometrial Cancer Treatment 0.516218 Recurrent endometrial cancer 0.629078 fallopian tubes 0.494755 cancer information summaries 0.469865 treatment options 0.466033 comprehensive cancer information 0.469896 internal radiation therapy 0.504839	CLICK HERE
1577	National Cancer Institute	Html	en	Retinoblastoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of retinoblastoma in children.	cancer treatment 0.489298 body 0.467706 type 0.422666 PDQ cancer information 0.456409 clinical trial search 0.418893 retinoblastoma 0.865388 retinoblastoma treatment centers 0.451209 systemic chemotherapy 0.574478 regular eye exams 0.443823 clinical trials 0.855386 recurrent intraocular retinoblastoma 0.415908 high-dose chemotherapy 0.465125 cancer information summary 0.42823 clinical trial 0.564195 patients 0.408556 eye 0.840016 radiation therapy 0.862799 optic nerve 0.459799 child 0.430789 heritable form 0.409154 treatment 0.773723 bilateral intraocular retinoblastoma 0.418197 heritable retinoblastoma 0.466245 Nonheritable retinoblastoma 0.41969 cancer cells 0.573196	extraocular retinoblastoma 0.479879 retinoblastoma cells 0.416299 Intravitreal chemotherapy 0.407999 treatment clinical trials 0.426091 RB1 gene 0.435629 National Cancer Institute 0.44282 spinal cord 0.437008 intraocular retinoblastoma 0.468181 effects cancer treatment 0.415229 new treatment 0.441768 artery infusion chemotherapy 0.538311 external-beam radiation therapy 0.642309 recurrent extraocular retinoblastoma 0.414269 ophthalmic artery infusion 0.504849 metastatic retinoblastoma 0.407008 trilateral retinoblastoma 0.466869 bone marrow 0.434989 cancer clinical trials 0.449674 cavitary retinoblastoma 0.436997 stem cell rescue 0.535096 tumor 0.495126 retinoblastoma spreads 0.40533 internal radiation therapy 0.438773 cancer 0.972687	CLICK HERE
1740	National Cancer Institute	Html	en	Hair Dyes and Cancer Risk	A fact sheet that reviews research about the possibility of a connection between personal hair dye use and cancer.	female breast cancer 0.364162 hair dye 0.94208 hair dye products 0.547022 hair dyes 0.824788 Kupelnick B. Personal 0.356107 Modern hair dyes 0.445893 C. Personal hair 0.381701 case-control study 0.408793 bladder cancer 0.729938 consumer exposure study 0.34979 permanent hair dye 0.484417 increased risk 0.395633 case-control studies 0.347772 bladder cancer risk 0.47239 Montes-Martinez A. Personal 0.354703 IARC Working Group 0.350056 permanent hair dyes 0.502056 MR. Bladder cancer 0.389163 American Journal 0.365295 temporary hair dyes 0.442658 hair coloring products 0.388447 currently marketed products 0.354822 leukemia/small lymphocytic lymphoma 0.349931 colorless dye 0.417079 A. Bladder cancer 0.391043	Cancer Epidemiology Biomarkers 0.364493 International Journal 0.379963 public health impact 0.349406 black permanent dyes 0.401612 color dyes 0.375257 Personal permanent hair 0.383955 United States 0.383182 adult acute leukemia 0.391088 non-Hodgkin lymphoma 0.350907 conflicting results 0.412706 bladder cancer study 0.39321 earlier hair dyes 0.42871 personal hair dye 0.756765 studies 0.389653 bladder-cancer risk 0.359564 public health 0.351318 dark-colored dyes 0.399225 follicular lymphoma 0.348182 recent dye formulations 0.42394 aromatic amines 0.360034 hair dye formulations 0.474224 specific NHL subtypes 0.351636 hair dye users 0.497516 et al 0.482744	CLICK HERE
1845	National Cancer Institute	Html	es	Tratamiento del cáncer primario de hígado en adultos (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer primario de hígado en adultos.	percutaneous ethanol 0.307629 Surg Oncol Clin 0.302767 hepatocellular carcinoma based 0.30936 hepatocellular carcinoma smaller 0.309339 early hepatocellular carcinoma 0.330465 quimioembolización arterial transcatéter 0.307969 versus surgical resection 0.303957 patients with cirrhosis 0.308968 European patients with 0.302703 with hepatocellular carcinoma 0.310631 carcinoma among us 0.306777 Bruix J 0.308485 ethanol injection therapy 0.303818 carcinoma with drug 0.307102 hepatocellular carcinoma 0.981778 BCLC staging classification 0.303901 carcinoma using 0.305993 small hepatocellular carcinoma 0.369666 hepatocellular carcinoma after 0.309033 estadificación tnm 0.30443 patients with 0.343761 radiofrequency ablation 0.30759 retrospective study 0.303001 Gastroenterol Hepatol 0.306642 AASLD hepatocellular carcinoma 0.309539	advanced hepatocellular carcinoma 0.325377 sorafenib versus 0.304969 untreated hepatocellular carcinoma 0.309351 estadificación okuda 0.306358 Lin CC 0.303335 after percutaneous ethanol 0.303796 recurrent hepatocellular carcinoma 0.318564 estadificación bclc 0.30882 Poon RT 0.307702 controlled trial 0.310604 Cancer Staging Manual 0.303852 Radiofrequency ablation versus 0.303706 Surg Oncol 0.303137 aflatoxina b1 0.304027 Clin Oncol 0.306158 Gastrointest Surg 0.303366 carcinoma up 0.306683 systematic review 0.303509 Llovet JM 0.316349 randomized controlled trial 0.310237 Cardiovasc Intervent Radiol 0.302772 cm hepatocellular carcinoma 0.310978 American Joint Committee 0.305624 prospective study 0.30533	CLICK HERE
1876	National Cancer Institute	Html	es	Tratamiento de los tumores de ovario de bajo potencial maligno (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores de ovario de bajo potencial maligno.	estadio lV 0.336073 Obstet Gynecol 0.332535 Are borderline tumors 0.338893 Radium Hospital from 0.383601 low malignant 0.947577 Norwegian Radium Hospital 0.384329 Abeler VM 0.345874 long-term follow-up 0.429878 serous tumors 0.367951 Leake JF 0.387334 ovary treated 0.34981 Instituto Nacional 0.327748 malignant potential with 0.326796 Rosenshein NB 0.34897 Federation Internationale 0.32197 University Medical Center 0.328522 Kaern J 0.406737 endometrioid tumors 0.337973 Gynecologic Oncology Group 0.336842 Gynecol Oncol 0.811816 lavados peritoneales 0.350751 New York University 0.326742 Icb Tumor 0.324006 retrospective study 0.363127 cellular dna content 0.335807	Bell DA 0.339598 patients with borderline 0.366646 malignant potential treated 0.323909 borderline tumors with 0.347412 borderline tumors 0.629125 clinicopathologic features 0.350407 tumores aneuploides 0.321014 estadio ia 0.33807 Oncology Group study 0.347633 with borderline tumors 0.383311 IIIa Tumor 0.323737 Kurman RJ 0.323851 PDQ Tratamiento 0.323544 Gynecol Pathol 0.337197 New York 0.330732 York University Medical 0.327419 Currie JL 0.350075 Ovarian epithelial tumors 0.334479 Clin Oncol 0.355682 Tropé CG 0.345953 Lage JM 0.321478 tumor residual macroscópico 0.331365 Gynecol Cancer 0.321099 serous borderline tumors 0.4289	CLICK HERE
3452	National Cancer Institute	Html	es	Planificar la transición para la atención del cáncer avanzado en la etapa final de la vida (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre la preparación necesaria por parte de los proveedores de atención de la salud, los pacientes y sus familias para la transición a la atención del cáncer avanzado en la etapa final de la vida.	etapa final 0.993589 aspectos espirituales.Quimioterapia 0.301674 PDQ Planificar 0.301661 enfermedad progresa 0.300844 Palliative Care Organization 0.301866 Organización Nacional 0.300803 Physician Data Query 0.304167 Estados Unidos 0.301443 practique reanimación cardiorrespiratoria 0.304362 National Hospice 0.300987 sección caring connections 0.30178	siguientes consejos 0.301301 cuánto tiempo 0.301394 reanimación cardiorrespiratoria 0.321909 familia hará frente 0.30286 cuidados paliativos 0.479509 National Cancer Institute 0.301056 cuidado paliativo 0.301307 siguientes riesgos 0.300668 decisiones conjuntas 0.304112 Instituto Nacional 0.301868	CLICK HERE
3520	National Cancer Institute	Html	en	Where Trials Take Place	Information about the various settings in which cancer clinical trials take place.	NCI-designated cancer centers 0.754234 veterans 0.437829 clinics 0.435881 United States 0.797764 single trial 0.604599 medical centers 0.598598 offices 0.436127 Cancer.gov clinical trials 0.786399 world 0.438646 NIH Clinical Center 0.734388 clinical trials 0.951404 place 0.614988 hundreds 0.437249 NCI network trials 0.778802	cities 0.438884 community hospitals 0.619062 different sites 0.602675 Cancer clinical trials 0.789309 doctor 0.455993 Canada 0.433786 places 0.435058 form 0.434135 doctors 0.439293 NCI-supported clinical trials 0.74928 military hospitals 0.617836 treatment options 0.580271 towns 0.446502 form. 0.434179	CLICK HERE
3678	National Cancer Institute	Html	en	NCI Outstanding Investigator Award Recipients	Learn how these investigators' projects aim to break new ground in biomedical, behavioral, and clinical cancer research.	Professor 0.818386 cancer cell fate 0.872486 tumor interstitial fluid 0.811256 Institution 0.848074 brain cancer stem 0.81847 Salk Institute Cancer 0.836669 cancer therapy 0.800257 ccRCC tumor metabolism 0.813028 cancer stem cell 0.87789 Harvard Medical School 0.902146 Institute Cancer Center 0.918217 Mount Sinai Cancer 0.82427 interactive research areas 0.831532 new therapeutic targets 0.831101 Tisch Cancer Institute 0.836924 tumor suppressor functions 0.808451 Cell Biology Laboratory 0.802354 clinical cancer research 0.915827 Hopkins University School 0.800509 Medical Research 0.805386 molecular mechanisms 0.847735 human cancer metabolism 0.844789 kidney cancer subtype 0.813888 Cancer Research Program 0.87416 mouse models 0.817082	leukemia cell metabolism 0.821118 Cancer Research Center 0.897578 cancer cell metabolism 0.867114 cancer cells 0.87218 Stem Cell Biology 0.799482 distinct cell types 0.801724 Anderson Cancer Center 0.828569 cancer research 0.977431 Adolphus Pfeiffer Professor 0.801659 HGG cancer cell 0.848375 tumor suppressor gene 0.80279 Center Research Institute 0.861555 Title 0.835958 Cancer Society Research 0.870208 Stem Cell Research 0.847258 Cell Biology 0.815108 tumor microenvironment signals 0.812505 Cancer Imaging Research 0.895426 Cell Biology Department 0.805035 acute lymphoblastic leukemia 0.839865 Bakar Distinguished Professor 0.809836 Wistar Institute Cancer 0.864712 M. Temin Professor 0.801808 tumor microenvironment 0.889603	CLICK HERE
16845	National Cancer Institute	Html	en	Masimo Corporation — Mechanical Drugs: Harnessing Cancer Aggressiveness to Overcome Its Resistance	Developing a new therapeutic approach to triple negative breast cancer (TNBC) which is based on intracellular mechanical impact generated by plasmonic nanobubbles.	synergy 0.336432 gold nanoparticles 0.550066 liposome-encapsulated drugs 0.504619 M.D. 0.377619 intracellular gold nanoparticle 0.766413 project team 0.493532 chemotherapy 0.340382 bubble generation threshold 0.657269 short laser pulse 0.734768 Ph.D. 0.365843 TNBC 0.333035 higher selectivity 0.504113 goal 0.33328 accumulation 0.342776 absorption 0.340473 negative breast cancer 0.692185 nanomaterials 0.340596 Co-Investigators 0.334002 plasmonic nanobubbles 0.543572 Principal Investigators 0.516256 Resistance 0.336765 radiotherapy 0.347319 Masimo Corporation 0.532528 Mechanical Drugs 0.555482 EGFR-expressing cancer cells 0.691288	Vladimir Torchilin 0.519417 optical energy 0.499453 Ph.D 0.376534 larger gold clusters 0.685801 mechanical impact 0.858201 modalities 0.337622 radiation oncology 0.496973 Mien-Chie Hung 0.526833 nanobubble-disrupted liposomes 0.520675 Cancer Aggressiveness 0.580782 normal cells 0.511798 laser pulse 0.92023 Gillenwater 0.333958 Jack Phan 0.537018 host cell 0.497762 non-stationary vapor bubbles 0.750751 gold nanoclusters 0.536739 new therapeutic approach 0.68193 Nie 0.367583 Dmitri Lapotko 0.533767 molecular / cell 0.487681 low-energy laser pulse 0.711917 intracellular mechanical impact 0.751573 cancer biology 0.50282	CLICK HERE